Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 170-179

  Tang, Liangdan ^a   Yang, Junzheng ^a   Ng, Shu Kay ^b   Rodriguez, Noah ^a   Choi, Pui Wah ^c   Vitonis, Allison ^a   Wang, Kui ^d   McLachlan, Geoffrey J ^d   Caiazzo Jr , Robert J ^a   Liu, Brian C S ^a   Welch, William R ^a   Cramer, Daniel W ^a   Berkowitz, Ross S ^a   Ng, Shu Wing ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GRIFFITH UNIVERSITY   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Autoantibody; Ovarian cancer; Profiling; Signalling pathway; Smoking

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; TOBACCO SMOKE; WNT PROTEIN;

ANTIBODY DETECTION; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOKING;

ADENOCARCINOMA, MUCINOUS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 71249149587     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.003     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts and figures. American Cancer Society, Inc; 2004.
2. Bast Jr. R.C., Boyer C.M., Olt G.J., et al. Identification of marker for early detection of epithelial ovarian cancer (1990), Chapman and Hall, London, England
3. Serov S.F., and Scullt R.E. Histological typing of ovarian tumors (1993), World Health Organization, Geneva
4. Vergote I., De Brabanter J., Fyles A., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357 9251 (2001) 176-182
5. Harrison M.L., Jameson C., and Gore M.E. Mucinous ovarian cancer. Int J Gynecol Cancer 18 2 (2008) 209-214
6. Puls L.E., Powell D.E., DePriest P.D., et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47 1 (1992) 53-57
7. Ichikawa Y., Nishida M., Suzuki H., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54 1 (1994) 33-35
8. Mok S.C., Bell D.A., Knapp R.C., et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53 7 (1993) 1489-1492
9. Wamunyokoli F.W., Bonome T., Lee J.Y., et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 12 3 Pt 1 (2006) 690-700
10. Hess V., A'Hern R., Nasiri N., et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22 6 (2004) 1040-1044
11. Marchbanks P.A., Wilson H., Bastos E., et al. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 95 2 (2000) 255-260
12. Modugno F., Ness R.B., and Cottreau C.M. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology 13 4 (2002) 467-471
13. Zhang Y., Coogan P.F., Palmer J.R., Strom B.L., and Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol 159 2 (2004) 133-139
14. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 5897 (2008) 1807-1812
15. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 5897 (2008) 1801-1806
16. Chinni S.R., Falchetto R., Gercel-Taylor C., et al. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res 3 9 (1997) 1557-1564
17. Korneeva I., Bongiovanni A.M., Girotra M., Caputo T.A., and Witkin S.S. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol 183 1 (2000) 18-21
18. Gnjatic S., Atanackovic D., Jager E., et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100 15 (2003) 8862-8867
19. Frenkel K., Karkoszka J., Glassman T., et al. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol Biomarkers Prev 7 1 (1998) 49-57
20. Hu J.J., Chi C.X., Frenkel K., et al. Alpha-tocopherol dietary supplement decreases titers of antibody against 5-hydroxymethyl-2'-deoxyuridine (HMdU). Cancer Epidemiol Biomarkers Prev 8 8 (1999) 693-698
21. Lubin R., Zalcman G., Bouchet L., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1 7 (1995) 701-702
22. Caron M., Choquet-Kastylevsky G., and Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6 7 (2007) 1115-1122
23. Wang Y., Han K.J., Pang X.W., et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169 2 (2002) 1102-1109
24. Hudson M.E., Pozdnyakova I., Haines K., Mor G., and Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 104 44 (2007) 17494-17499
25. Hong S.H., Misek D.E., Wang H., et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64 15 (2004) 5504-5510
26. Tomaino B., Cappello P., Capello M., et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 6 10 (2007) 4025-4031
27. Madoz-Gurpide J., Kuick R., Wang H., Misek D.E., and Hanash S.M. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 7 2 (2008) 268-281
28. Ehrlich J.R., Qin S., and Liu B.C. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 1 1 (2006) 452-460
29. Ehrlich J.R., Tang L., Caiazzo Jr. R.J., et al. The reverse capture autoantibody microarray: an innovative approach to profiling the autoantibody response to tissue-derived native antigens. In: Ehrlich J.R., and Liu B.C. (Eds). Tissue proteomics - pathways, biomarkers, and drug discovery (2008), Humana Press, New Jersey 175-192
30. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98 9 (2001) 5116-5121
31. McLachlan G.J., Bean R.W., and Jones L.B. A simple implementation of a normal mixture approach to differential gene expression in multiclass microarrays. Bioinformatics 22 13 (2006) 1608-1615
32. Qin S., Qiu W., Ehrlich J.R., et al. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6 10 (2006) 3199-3209
33. Dennis Jr. G., Sherman B.T., Hosack D.A., et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4 5 (2003) P3
34. Tatsumi T., Herrem C.J., Olson W.C., et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63 15 (2003) 4481-4489
35. Zhang J., and Chan E.K. Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev 1 3 (2002) 146-153
36. Chatterjee M., Mohapatra S., Ionan A., et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66 2 (2006) 1181-1190
37. Lang G.A., and Yeaman G.R. Autoantibodies in endometriosis sera recognize a Thomsen-Friedenreich-like carbohydrate antigen. J Autoimmun 16 2 (2001) 151-161
38. Yeaman G.R., Collins J.E., and Lang G.A. Autoantibody responses to carbohydrate epitopes in endometriosis. Ann N Y Acad Sci 955 (2002) 174-182 [discussion 199-200, 396-406]
39. Novak A., and Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 56 5-6 (1999) 523-537
40. Shield K., Riley C., Quinn M.A., et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6 (2007) 11
41. Ahmed N., Riley C., Rice G., and Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 22 5 (2005) 391-402
42. Kishikawa T., Sakamoto M., Ino Y., et al. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis 15 1-2 (1995) 11-21
43. Sarrio D., Moreno-Bueno G., Sanchez-Estevez C., et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 37 8 (2006) 1042-1049
44. Kildal W., Risberg B., Abeler V.M., et al. Beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 41 8 (2005) 1127-1134
45. Marzo N., Ortega S., Stratmann T., et al. Cyclin-dependent kinase 4 hyperactivity promotes autoreactivity in the immune system but protects pancreatic cell mass from autoimmune destruction in the nonobese diabetic mouse model. J Immunol 180 2 (2008) 1189-1198
46. Yang Y.G., Lindahl T., and Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131 5 (2007) 873-886
47. Hur J.W., Sung Y.K., Shin H.D., et al. TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus. Rheumatol Int 28 8 (2008) 783-789
48. Delunardo F., Conti F., Margutti P., et al. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behcet's disease. Arthritis Res Ther 8 3 (2006) R71